Lumos Pharma, Inc. (LUMO)

USD 4.34

(0.0%)

Market Cap (In USD)

37.53 Million

Revenue (In USD)

2.05 Million

Net Income (In USD)

-34.03 Million

Avg. Volume

102.97 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.37-4.58
PE
-1.014
EPS
-4.28
Beta Value
0.331
ISIN
US55028X1090
CUSIP
55028X109
CIK
1126234
Shares
8648620.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Richard J. Hawkins
Employee Count
-
Website
https://www.lumos-pharma.com
Ipo Date
2011-11-11
Details
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.